Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-Center, Placebo-Controlled, Dose-Ranging Phase 2 Electrophysiological Study of Intranasal Administration of MSP-2017 for the Conversion of Induced Paroxysmal Supraventricular Tachycardia (PSVT) to Sinus Rhythm

NCT02296190 is registered in ClinicalTrials.gov with Milestone Pharmaceuticals Inc. as lead sponsor.

NCT NCT02296190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02296190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-Center, Placebo-Controlled, Dose-Ranging Phase 2 Electrophysiological Study of Intranasal Administration of MSP-2017 for the Conversion of Induced Paroxysmal Supraventricular Tachycardia (PSVT) to Sinus Rhythm
Lead sponsor
Milestone Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 27, 2015
Completion date
December 31, 2016
Enrollment
199 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

paroxysmal supraventricular tachycardia (psvt)